ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours - European Medical Journal

ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours

Oncology

RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US, showed that treatment with the mTOR inhibitor, everolimus, had a significant effect in non-functional neuroendocrine tumours (NETs). There was a statistically significant 52% reduction in the risk of progression or death in favour of everolimus, and also a clinically meaningful 2.8 fold (7.1 months) improvement in median progression-free survival compared with those who had taken placebo.

Presented at the European Cancer Conference (ECC) 2015 by James Yao, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>